Discovery of quinoline-based derivatives as c-Met inhibitors for the treatment of non-small cell lung cancer.
The design, synthesis, and biological evaluation of a novel series of type II c-Met inhibitors bearing α-amino acid-derived linkers and a morpholinopropoxy quinoline scaffold position compound 41 as a promising lead for the development of next-generation, tolerable c-Met targeted therapeutics.